{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T08:21:12Z","timestamp":1787473272849,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Paediatric Respiratory Reviews"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.prrv.2026.01.004","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T16:49:43Z","timestamp":1769618983000},"page":"3-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Detection of Pseudomonas aeruginosa in cystic fibrosis after initiation of CFTR modulators: a systematic review"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1106-4424","authenticated-orcid":false,"given":"Vito","family":"Terlizzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9486-8400","authenticated-orcid":false,"given":"Edoardo","family":"Timitilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Sole","family":"Fiumara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Dolce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Chiappini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.prrv.2026.01.004_b0005","article-title":"Considerations for the use of inhaled antibiotics for Pseudomonas aeruginosa in people with cystic fibrosis receiving CFTR modulator therapy","volume":"11","author":"Burgel","year":"2024","journal-title":"BMJ Open Respir Res"},{"issue":"5","key":"10.1016\/j.prrv.2026.01.004_b0010","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jcf.2014.08.001","article-title":"Early detection of infection with Pseudomonas aeruginosa in cystic fibrosis: the Holy Grail or an achievable goal?","volume":"13","author":"Taccetti","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.prrv.2026.01.004_b0015","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s00431-024-05905-9","article-title":"Antibiotic treatment of bacterial lung infections in cystic fibrosis","volume":"184","author":"Taccetti","year":"2024","journal-title":"Eur J Pediatr"},{"issue":"9","key":"10.1016\/j.prrv.2026.01.004_b0020","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/1471-2180-9-244","article-title":"Comparison of the sensitivity of culture, PCR and quantitative real-time PCR for the detection of Pseudomonas aeruginosa in sputum of cystic fibrosis patients","volume":"29","author":"Deschaght","year":"2009","journal-title":"BMC Microbiol"},{"issue":"5","key":"10.1016\/j.prrv.2026.01.004_b0025","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jcf.2025.06.002","article-title":"Monitoring early antibiotic treatment with anti-Pseudomonas aeruginosa serology: a comparison of two specific antibody panels","volume":"24","author":"Dolce","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"19","key":"10.1016\/j.prrv.2026.01.004_b0030","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.prrv.2026.01.004_b0035","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.prrv.2026.01.004_b0040","first-page":"e00787","article-title":"Cystic fibrosis pathogens persist in the upper respiratory tract following initiation of elexacaftor\/tezacaftor\/ivacaftor therapy","volume":"12","author":"Hilliam","year":"2024","journal-title":"Jun SR, editor Microbiol Spectr"},{"key":"10.1016\/j.prrv.2026.01.004_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2025.08.019","article-title":"Factors associated with sustained Pseudomonas aeruginosa infection following elexacaftor\/tezacaftor\/ivacaftor treatment: real-world data from the European cystic fibrosis society patient registry","author":"Pollak","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2026.01.004_b0050","doi-asserted-by":"crossref","DOI":"10.1177\/17534666251323194","article-title":"Cystic fibrosis: new challenges and perspectives beyond elexacaftor\/tezacaftor\/ivacaftor","volume":"19","author":"Terlizzi","year":"2025","journal-title":"Ther Adv Respir Dis"},{"issue":"10","key":"10.1016\/j.prrv.2026.01.004_b0055","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine","volume":"21","author":"Lopes-Pacheco","year":"2020","journal-title":"Front Pharmacol"},{"issue":"16","key":"10.1016\/j.prrv.2026.01.004_b0060","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.3390\/ijms21165882","article-title":"From ivacaftor to triple combination: a systematic review of efficacy and safety of CFTR modulators in people with cystic fibrosis","volume":"21","author":"Gramegna","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.prrv.2026.01.004_b0065","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"29","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.prrv.2026.01.004_b0070","unstructured":"Study Quality Assessment Tools | NHLBI, NIH [Internet]. [cited 2025 July 13]. Available from: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools."},{"key":"10.1016\/j.prrv.2026.01.004_b0075","doi-asserted-by":"crossref","unstructured":"Armbruster CR, Hilliam YK, Zemke AC, Atteih S, Marshall CW, Moore J, et al. Persistence and evolution of Pseudomonas aeruginosa following initiation of highly effective modulator therapy in cystic fibrosis. Lemon KP, editor. mBio. 2024 May 8;15(5):e00519-24.","DOI":"10.1128\/mbio.00519-24"},{"issue":"6","key":"10.1016\/j.prrv.2026.01.004_b0080","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.jcf.2024.02.013","article-title":"Role of viable but non culturable cells in patients with cystic fibrosis in the era of highly effective modulator therapy","volume":"23","author":"Cirilli","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.prrv.2026.01.004_b0085","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1002\/ppul.26485","article-title":"Impact of Elexacaftor\u2013Tezacaftor\u2013Ivacaftor on lung disease in cystic fibrosis","volume":"58","author":"Gushue","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"10.1016\/j.prrv.2026.01.004_b0090","doi-asserted-by":"crossref","first-page":"e536","DOI":"10.1093\/infdis\/jiae051","article-title":"Impact of CFTR modulation on Pseudomonas aeruginosa infection in people with cystic fibrosis","volume":"230","author":"Ledger","year":"2024","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.prrv.2026.01.004_b0095","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12931-023-02630-z","article-title":"Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor\u2013Tezacaftor\u2013Ivacaftor therapy","volume":"24","author":"Martin","year":"2023","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.prrv.2026.01.004_b0100","doi-asserted-by":"crossref","first-page":"29298","DOI":"10.1038\/s41598-024-77246-4","article-title":"One year of ETI reduces lung bacterial colonisation in adults with cystic fibrosis","volume":"14","author":"Mianowski","year":"2024","journal-title":"Sci Rep"},{"issue":"20","key":"10.1016\/j.prrv.2026.01.004_b0105","article-title":"Elexacaftor\/tezacaftor\/ivacaftor\u2019s effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment","volume":"134","author":"Morgan","year":"2024","journal-title":"J Clin Invest [Internet]"},{"issue":"10","key":"10.1016\/j.prrv.2026.01.004_b0110","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.prrv.2026.01.004_b0115","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02153-2022","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis","volume":"62","author":"Schaupp","year":"2023","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.prrv.2026.01.004_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e15756","article-title":"Elexacaftor \u2013 Tezacaftor \u2013 Ivacaftor treatment improves systemic infection parameters and Pseudomonas aeruginosa colonization rate in patients with cystic fibrosis a monocentric observational study","volume":"9","author":"Schnell","year":"2023","journal-title":"Heliyon"},{"issue":"5","key":"10.1016\/j.prrv.2026.01.004_b0125","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/ppul.26362","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on bacterial cultures from people with cystic fibrosis","volume":"58","author":"Beck","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.prrv.2026.01.004_b0130","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijid.2023.11.013","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor leads to changes in detection frequencies of Staphylococcus aureus and Pseudomonas aeruginosa dependent on age and lung function in people with cystic fibrosis","volume":"139","author":"Dittrich","year":"2024","journal-title":"Int J Infect Dis"},{"issue":"2","key":"10.1016\/j.prrv.2026.01.004_b0135","first-page":"135","article-title":"Effect of Elexacaftor\/Tezacaftor\/Ivacaftor on Pseudomonas aeruginosa acquisition and chronic infection at a single pediatric cystic fibrosis care center","volume":"29","author":"Duehlmeyer","year":"2024","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.prrv.2026.01.004_b0140","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1097\/INF.0000000000004580","article-title":"A three-year longitudinal assessment of Pseudomonas aeruginosa antibiotic susceptibility in children with cystic fibrosis in the era of cystic fibrosis transmembrane conductance regulator modulator therapy","volume":"44","author":"Stout","year":"2025","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.prrv.2026.01.004_b0145","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","article-title":"Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"2","author":"Lee","year":"2003","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.prrv.2026.01.004_b0150","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/(SICI)1099-0496(199911)28:5<321::AID-PPUL3>3.0.CO;2-V","article-title":"Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis","volume":"28","author":"Rosenfeld","year":"1999","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.prrv.2026.01.004_b0155","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00832-2017","article-title":"Airway microbiota across age and disease spectrum in cystic fibrosis","volume":"50","author":"Zemanick","year":"2017","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.prrv.2026.01.004_b0160","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jcf.2017.12.007","article-title":"One time quantitative PCR detection of Pseudomonas aeruginosa to discriminate intermittent from chronic infection in cystic fibrosis","volume":"17","author":"Boutin","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.prrv.2026.01.004_b0165","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1186\/s12879-018-3612-9","article-title":"Detection of viable but non-culturable Pseudomonas aeruginosa in cystic fibrosis by qPCR: a validation study","volume":"18","author":"Mangiaterra","year":"2018","journal-title":"BMC Infect Dis"},{"issue":"15","key":"10.1016\/j.prrv.2026.01.004_b0170","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1007\/s00253-020-10687-9","article-title":"Release mechanisms and molecular interactions of Pseudomonas aeruginosa extracellular DNA","volume":"104","author":"Sarkar","year":"2020","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.prrv.2026.01.004_b0175","doi-asserted-by":"crossref","unstructured":"Ferguson DL, Gloag ES, Parsek MR, Wozniak DJ. Extracellular DNA enhances biofilm integrity and mechanical properties of mucoid Pseudomonas aeruginosa. O\u2019Toole G, editor. J Bacteriol. 2023;205(10):e00238-23.","DOI":"10.1128\/jb.00238-23"},{"issue":"10","key":"10.1016\/j.prrv.2026.01.004_b0180","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.4049\/jimmunol.1301589","article-title":"Release of cystic fibrosis airway inflammatory markers from Pseudomonas aeruginosa \u2013stimulated human neutrophils involves NADPH oxidase-dependent extracellular DNA trap formation","volume":"192","author":"Yoo","year":"2014","journal-title":"J Immunol"}],"container-title":["Paediatric Respiratory Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054226000059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054226000059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T07:48:50Z","timestamp":1787471330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526054226000059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":36,"alternative-id":["S1526054226000059"],"URL":"https:\/\/doi.org\/10.1016\/j.prrv.2026.01.004","relation":{},"ISSN":["1526-0542"],"issn-type":[{"value":"1526-0542","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Detection of Pseudomonas aeruginosa in cystic fibrosis after initiation of CFTR modulators: a systematic review","name":"articletitle","label":"Article Title"},{"value":"Paediatric Respiratory Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prrv.2026.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}